Self‐Carrier Nanovaccines Codelivering Paclitaxel and Tumor Cell Lysates for Enhanced Antitumor Chemo‐Immunotherapy

The combination of chemotherapy and immunotherapy has brought conspicuous clinical benefits for various solid tumors. Herein, self‐carrier nanovaccines (PS@TCL NVs) were engineered through coassembly of paclitaxel (PTX) prodrugs (PSSP) with tumor cell lysates (TCL). PS@TCL NVs can realize nanotechnology‐promoted tumor accumulation. Upon cellular internalization, PS@TCL NVs can respond to redox stimuli and trigger the release of PTX and TCL. The released PTX can kill cancer cells by microtubule interference‐induced mitosis disorder, which concurrently causes potent immunogenic cell death (ICD), leading to cascaded maturation of dendritic cells and recruitment and activation of cytotoxic T lymphocytes. Simultaneously, released TCL antigens activate tumor‐specific T cells, thus amplifying antitumor immunity to achieve effective tumor treatment. This study offers insights into the development of simple, user‐friendly platforms tailored for precise clinical applications.